In summary, we found that SOX1 is downregulated expression in CCA patients, it suppressed the RAF/MEK/ERK pathway by decreasing the phosphorylation of RAF, MEK, and ERK, and inhibited the proliferation of CCA cells in vitro and suppressed tumor growth in vivo. This evidence concerns the gene MAP2K7 and cholangiocarcinoma.